GlobeStar Therapeutics Corp (GSTC)

[Convive]

“If Liprostin™ treated ten percent (10%) of the 12 million untreated Peripheral Artery Disease patients in the U.S. as reported by The American Heart Association, this could produce a gross income of six hundred million dollars ($600 million) if we assumed the Company yields five hundred dollars ($500) per patient,” said Ms. Alexanderia K Blankenship, CEO & President of AngioSoma, Inc.